[HTML][HTML] HIV相关弥漫大B细胞淋巴瘤预后评估生物学标志物研究进展*
唐鑫怡， 张亚坤， 陈双， 彭余， 蒋亭亭… - 中国生物工程 …, 2024 - manu60.magtech.com.cn
… treatment, poor prognosis, and high mortality rate. Currently, the international prognostic index
(IPI… HIV-associated DLBCL patients with high risks and poor prognosis. In response to the …
(IPI… HIV-associated DLBCL patients with high risks and poor prognosis. In response to the …
[PDF][PDF] 鷺PLOS| O NE
T Nishijima, M Takano, S Matsumoto, M Koyama… - 2015 - mhlw-grants.niph.go.jp
… with a survival advantage. PloS Pathog 2008; 4:e1000033. … multiple medications and frequent
changes are made to their … we used HAART drugs to HIV-infected patients whose CD4 cell …
changes are made to their … we used HAART drugs to HIV-infected patients whose CD4 cell …
改善非洲馬拉威北部公共衛生的相關研究: 傳統接生婆受訓後的表現與愛滋病人接受治療的存活分析
陳志成 - 2010 - tdr.lib.ntu.edu.tw
… analyzing survival rates of AIDS patients on antiretroviral therapy for … in decreasing the
neonatal mortality rate to less than half of the … Changes in proportion of correct answers among 25 …
neonatal mortality rate to less than half of the … Changes in proportion of correct answers among 25 …
[HTML][HTML] 18岁及以上HIV感染者抗病毒治疗后CD4+T淋巴细胞计数水平比较
郭小茜， 马烨， 豆智慧， 吴亚松， 赵德才， 蔡卫平… - 中华流行病学 …, 2017 - html.rhhz.net
… CD 4 + T lymphocyte responses to anti-retroviral therapy, among HIV/… Poor initial CD 4 +
recovery with antiretroviral therapy … Mortality and immunological recovery among older adults on …
recovery with antiretroviral therapy … Mortality and immunological recovery among older adults on …
[HTML][HTML] HIV 抗病毒治疗与疫情关联的研究进展
丁中兴， 卢珍珍， 王璐， 汪宁， 彭志行 - 中华流行病学杂志, 2020 - html.rhhz.net
… 首先采用了抗病毒治疗(antiretroviral therapy,ART),发展中国家… 分别为是否接受HAART和首次
接受HAART时CD 4 + T淋巴细胞… 学者通过追踪31 070名患者的CD 4 + T淋巴细胞计数,发现ART…
接受HAART时CD 4 + T淋巴细胞… 学者通过追踪31 070名患者的CD 4 + T淋巴细胞计数,发现ART…
[HTML][HTML] 台州市2017-2018 年新报告HIV/AIDS 巨细胞病毒血症现患率及影响因素研究
乔世杰， 周素娟， 徐璐璐， 陈潇潇， 许圆圆， 沈伟伟… - 中华流行病学 …, 2021 - html.rhhz.net
… that the risk of CMV viremia in CD 4 + lymphocyte cells counts (CD 4 + ) ≤ 200 … , mortality,
and end-organ disease among patients with AIDS receiving potent antiretroviral therapies[J]. J …
and end-organ disease among patients with AIDS receiving potent antiretroviral therapies[J]. J …
[HTML][HTML] 四川省部分地区HIV-1 感染者二线方案抗病毒治疗效果及耐药突变分析
袁丹， 李一平， 杨淑娟， 刘芳， 黄晓玲， 姚亮， 李玲… - 中华流行病学 …, 2023 - html.rhhz.net
… The changes of CD4 + T lymphocytes (CD4) counts and viral … 2.55 times higher risk than that
of timely changing to the second… -term clinical outcomes in antiretroviral therapy in Guangxi, …
of timely changing to the second… -term clinical outcomes in antiretroviral therapy in Guangxi, …
[PDF][PDF] HIV 感染/AIDS 合并结核病的临床及免疫学特点研究进展
郭静， 沈银忠 - 诊断学理论与实践, 2021 - qk.sjtu.edu.cn
… Mortality in adults with multidrugrresistant tuberculosis and HIV by antiretroviral therapy and
… NFrkappa B activar tion and cytotoxicity by altering the cellular redox state [J]. EMBO J,1995,…
… NFrkappa B activar tion and cytotoxicity by altering the cellular redox state [J]. EMBO J,1995,…